Approximately 24,740 malignant brain and spinal cord tumors are projected to be diagnosed in the United States in 2026, with 18,350 deaths expected and an overall 5-year relative survival rate near 32.9%. Outcomes worsen sharply with age: in a SEER analysis of more than 40,000 patients with glioblastoma, median survival was 4 months in patients older than 65 versus 19 months in younger patients. AAVBC’s perspective is clear: new cognitive, personality, gait, or focal neurologic changes in an older adult should not be dismissed as normal aging. Early recognition, distinction between primary and metastatic disease, and documentation of active treatment or surveillance status directly shape care coordination and risk adjustment.
AAVBC's Brain Cancer Quick Reference Guide translates NCCN v1.2026 guidance and CMS-HCC V28 methodology into practical support for atypical presentations, geriatric assessment, molecular-subtype treatment pathways, MEAT documentation, ICD-10 specificity, and case-based coding.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of brain cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Approximately 24,740 malignant brain and spinal cord tumors are projected to be diagnosed in the United States in 2026, with 18,350 deaths expected and an overall 5-year relative survival rate near 32.9%. Outcomes worsen sharply with age: in a SEER analysis of more than 40,000 patients with glioblastoma, median survival was 4 months in patients older than 65 versus 19 months in younger patients. AAVBC’s perspective is clear: new cognitive, personality, gait, or focal neurologic changes in an older adult should not be dismissed as normal aging. Early recognition, distinction between primary and metastatic disease, and documentation of active treatment or surveillance status directly shape care coordination and risk adjustment.
AAVBC's Brain Cancer Quick Reference Guide translates NCCN v1.2026 guidance and CMS-HCC V28 methodology into practical support for atypical presentations, geriatric assessment, molecular-subtype treatment pathways, MEAT documentation, ICD-10 specificity, and case-based coding.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of brain cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
